-Super Speed of Only Nine Months

Renova is exploring new therapeutic opportunities that have the potential to expand the use of Renova’s gene therapy platform to include several pathologies associated with diabetes and heart failure.

Renova Has Prioritized Two Primary Regulatory Pathways Where It Is Poised to Launch Pivotal Human Trials for Its Promising Gene Therapies to Treat Heart Failure and Type 2 Diabetes Mellitus

FIRST INVESTMENT FROM CMTA’S NEW VENTURE PHILANTHROPY ARM

The Sickle Cell Consortium Presents the 3rd Annual Sickle Cell Caregivers Summit Nov. 16-19, 2023

The Oct. 2-3 hybrid workshop will bridge the gap between critical stakeholders to pinpoint today's challenges and create forward-thinking solutions that enable the cell and gene therapy industry to create and deliver life-saving treatments equitably.

Sapio's No-Code ELN to Provide Enhanced Collaboration, Unified Data Access, and Flexible Workflows to viral vector CDMO Oxford Biomedica

Sapio's No-Code ELN to Provide Enhanced Collaboration, Unified Data Access, and Flexible Workflows to viral vector CDMO Oxford Biomedica

CGT cGMP Production Facilities in US and China

Forecyte Bio, CGT CDMO leader, officially opened its cGMP production suites for plasmid DNA, viral vector and cell therapy productions.

AmplifyBio announces $50M in debt financing to accelerate the expansion of its service offering, supporting the rapid, safe development of next-generation therapeutics

The Global Community of Hematopoietic Cell Transplantation and Cellular Therapy Specialists will Gather for the 2023 Tandem Meetings to Improve the Lives of Patients with Blood-Related Disorders and Solid Tumors.

Experienced operational executive to lead OcyonBio through its next stage of growth

OcyonBio CDMO welcomes cell and gene therapy expert Robert Salcedo who brings over 20 years of expertise in the areas of CMC, operations, and supply chain management and has served in multi-billion-dollar companies operating in biotech, vaccines, and pharmaceutical markets.

Renova Therapeutics Inc, a leader in the development of gene therapies for cardiovascular diseases and diabetes, announced the appointment of Dr. Vijay Mahant to the position of CEO, effective as of Sept. 16, 2021.

Single-use bioreactors market is estimated to attain a CAGR of 20.2% through 2027 owing to various advantages such as reduced cross contamination, cost-effectiveness, flexibility and increased productivity.

New 25,000-square-foot state-of-the-art cGMP manufacturing facility in West Sacramento, CA, quadruples manufacturing capacity as the company continues to remain focused on serving the cell and gene therapy market

This is an IRB-approved clinical trial aimed at reversing aging in humans. It is being conducted as a pay-to-play trial with a $1 million price tag to enroll.

Small nonprofit run by parent volunteers seeking to make a big impact and save their children

Every year, The Medicine Maker, a leading, global publication in cell and gene therapy, lists the world's top 100 thought leaders and opinion shapers who have carried out life-changing work in the biopharmaceutical industry, helping thousands of people across the globe.

World Stem Cell Summit and Phacilitate Leaders World to bring FOUR Meetings Together to Create Collaboration Needed to Deliver Global Cell and Gene Therapies!

ISCT confirmed as strategic partner for Phacilitate's trade mission to Asia, June 2018

Bringing mental health professionals and genetic scientists together.

Results of Poll on Gene Therapy Net. More than 60% of the people are of the opinion that gene therapy will be a vital part of future health care

StemCellRegenMed today announces, as a result of its continued ground-breaking efforts to treat Tay-Sachs disease through stem cell gene therapy, the treatment of three children suffering from this devastating genetic disorder.

Synpromics is pleased to announce that Andrei Lyne has joined the company as Chief Financial Officer. The new appointment demonstrates Synpromics's commitment to build a world-class management team to fully exploit its innovative technology.

Synpromics announces it incorporation as Scotland's latest biotech company. The new company aims to focus its activities in the area of synthetic mammalian biology and has acquired a number of patent applications submitted by Dr Michael Roberts.